Maligne Lebertumoren – Früherkennung und lokale Behandlung
| Autor: | G. Hübner, E. Lotterer, J Leßke, W.E. Fleig |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Cirrhosis Orthotopic liver transplantation Tumor size Radiofrequency ablation business.industry medicine.medical_treatment Gastroenterology Impaired liver function Octreotide medicine.disease Surgery law.invention law Hepatocellular carcinoma medicine Percutaneous ethanol injection business medicine.drug |
| Zdroj: | Visceral Medicine. 18:128-133 |
| ISSN: | 2297-475X 2297-4725 |
| DOI: | 10.1159/000064169 |
| Popis: | Malignant Liver Tumors – Early Detection and Local Treatment Hepatocellular carcinoma (HCC) is one of the five most common malignancies world-wide. In the Western world, it is predominantly found in patients with cirrhosis. The prognosis of untreated HCC is poor. In patients with overt symptoms of HCC, mean survival does not exceed 3–6 months. Surgical resection and orthotopic liver transplantation are the current options for curative treatment. Unfortunately, most lesions are not amenable to surgical treatment because of tumor size and location, impaired liver function, and co-morbidity. Therefore, early diagnosis of HCC is crucial, especially in populations at high risk. If a surgical option does no longer exist, local ablative therapies such as transarterial chemoembolization, percutaneous ethanol injection and radiofrequency ablation are alternatives. Until now, systemic drug treatment failed to prove its effectiveness or, much like octreotide and thymostimulin, is still in the phase of clinical testing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|